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TO THE EDITOR
Obesity has increased alarmingly during
recent decades in the Western world and
is a risk factor for several cancers (World
Cancer Research Fund, 2007; Lahmann
et al., 2010). However, evidence has not
been fully established for an asso-
ciation between obesity and malignant
melanoma (MM) and non-melanoma
skin cancer (NMSC). Recently, results
from a large meta-analysis showed that
men with high body mass index (BMI)
had an increased risk for MM, whereas
no association between BMI and risk
for MM was found among women
(Sergentanis et al., 2013). Fewer
studies have addressed the associations
between BMI and risk for NMSC and
the results are conflicting (Gerstenblith
et al., 2012; Nagel et al., 2012;
Pothiawala et al., 2012). However, the
vast majority of studies used only BMI
as a measure of obesity, although it is
increasingly accepted that hip circum-
ference (HC), waist circumference
(WC), and waist:hip ratio (WHR) more
accurately reflect a person’s body fat
distribution (Pischon et al., 2008).
We here addressed the association
between obesity, measured as BMI,
WC, HC, and WHR, and risks for MM
and NMSC, by the use of data from the
prospective Danish Diet, Cancer, and
Health Cohort study including 57,053
participants enrolled from 1993 to 1997.
A detailed description of the cohort has
been provided elsewhere (Tjonneland
et al., 2007). At the time of study
enrollment, i.e., at baseline, informa-
tion on anthropometric measures
was obtained by trained healthcare
professionals who measured height,
weight, WC, and HC by standardized
procedures (Rinaldi et al., 2012).
Information on potential confounders,
including skin reaction to the sun and
numbers of freckles and moles on the
arms, was obtained from questionnaires,
whereas information on vital status and
migration was obtained from linkage to
the Central Population Register. MM
cases diagnosed in the cohort during
the study period were identified by
linkage to the Danish Cancer Registry,
whereas all NMSC cases were identified
through linkage to an already establi-
shed NMSC database (Birch-Johansen
et al., 2010), which contains all
incident cases of basal cell carcinoma
(BCC) and squamous cell carcinoma
(SCC) diagnosed in Denmark registered
in either the Danish Cancer Registry or
in the Danish Registry of Pathology.
Incident skin cancers from the Danish
Cancer Registry were classified accord-
ing to the International Classification of
Diseases, 10th edition (ICD-10), codes
C43 (MM) and C44 (NMSC) and to the
International Classification of Diseases
Oncology 3rd edition (ICD-O-3), as
MM (morphology codes M-872–879),
BCC (M-809), or SCC (M-807). Data
on NMSC cases from the Danish
Registry of Pathology were classified
by Danish SNOMED classification
topography codes T01 and T02 and
relevant morphology codes as either
BCC (M-809) or SCC (M-807). From
both registries, only invasive cancers
were included (morphology codes with
‘3’ as the last digit). Each cohort
member was followed from date of
cohort entry until diagnosis of MM,
BCC and/or SCC, date of death/
emigration, or end of follow-up on 31
December 2010.
In a Cox proportional hazard model,
we examined associations between the
various anthropometric measures and
gender-specific rates of MM, BCC, and
SCC. We used age as the underlying
time axis to ensure that all analyses
were based on comparisons of cohort
members at the same age. Time under
study was included as the time-depen-
dent variable and modeled by a linear
spline. Two-sided 95% confidence
intervals (CIs) for estimated hazard ratios
(HRs) were calculated with the Wald
test of the Cox regression parameter.
In all, 26,685 men and 29,243 women
were eligible for analysis (Supplemen-
tary Figure S1 online). A total of 357
cohort members developed MM, 3,465
developed BCC, and 341 developed
SCC within a median follow-up period
of 14.4 years. Table 1 shows the dis-
tribution according to quartile of BMI of
the study participants. In general, men
had higher WC and WHR compared
with women, whereas women had a
higher HC compared with men.
No convincing associations were
found between the anthropometric mea-
sures and risk for MM (Supplementary
Table S1 online). Women with a BMI in
the highest quartile had a decreased risk
for BCC of 0.67 (95% CI: 0.54–0.82) in
comparison with women with a BMI in
the lowest quartile, whereas no associa-
tion was found between higher BMI and
risk for BCC in men. Among women,
every 2 kg m 2 increase in BMI was
associated with a decreased risk for
BCC of 0.90 (95% CI: 0.86–0.94).
Inverse linear dose–response associa-
tions were observed between increasing
WC and WHR and risk for BCC in both
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genders and between increasing HC and
risk for BCC among women but not
among men (Table 2). No associations
were observed between the anthropo-
metric measures and risk for SCC among
men. Among women, WC, HC, and
WHR did not affect the risk for SCC,
but every 2 kg m2 increase in BMI was
associated with a decreased risk of 0.80
(95% CI: 0.68–0.94) (Supplementary
Table S2 online).
Our null findings for MM correspond
with results from a meta-analysis by
Olsen et al. (2008). Results from two
other meta-analyses (Renehan et al.,
2012; Sergentanis et al., 2013), observed
an increased risk for MM among men
with higher BMI but no association
among women. In line with our results,
most previous studies also observed an
inverse association between BMI and
risk for BCC. In one of the largest
cohort studies to date, Pothiawala
et al. (2012) observed that obese parti-
cipants with a BMI 430 kg m 2 had a
19% lower risk for BCC compared with
participants with a BMI o25 kg m2.
The only previous study of the associa-
tion between measures of obesity other
than BMI and risk for BCC found no
convincing associations between WC
and WHR and risk for BCC (Olsen
et al., 2006). Two cohort studies have
investigated the association between
BMI and SCC: In agreement with our
study, Pothiawala et al. (2012) found
that increasing BMI was associated with
a decreasing risk for SCC among women
but not among men, whereas Nagel
et al. (2012) found no association with
BMI in either gender.
Hence, despite the fact that several
biological mechanisms link obesity to
cancer risk (Calle and Kaaks, 2004), our
results, which are in accordance with
the majority of other studies, indicate an
inverse association between obesity and
risk for NMSC even after adjustment for
potentially confounding factors related
to UV radiation (UVR) susceptibility.
However, the main limitation of our
Table 1. Characteristics of 55,928 participants enrolled in the Danish Diet, Cancer, and Health study (1993–2007)
according to BMI
Characteristic
Quartile of BMI (kg m 2)
1 2 3 4
No. of participants (%) 11,962 (21.4%) 12,950 (23.2%) 14,225 (25.4%) 16,792 (30.0%)
Men 6,204 (23.3%) 6,605 (24.8%) 5,993 (22.5%) 7,883 (29.5%)
Women 5,758 (19.7%) 6,345 (21.7%) 8,231 (28.2%) 8,909 (30.5%)
No. of participants with MM (%) 76 (21.3%) 81 (22.7%) 93 (26.1%) 107 (30.0%)
Men 37 (19.7%) 42 (22.3%) 44 (23.4%) 65 (34.6%)
Women 39 (23.1%) 39 (23.1%) 49 (29.0%) 42 (24.9%)
No. of participants with BCC (%) 861 (24.9%) 896 (25.9%) 898 (25.9%) 810 (23.4%)
Men 429 (25.7%) 475 (28.4%) 384 (23.0%) 383 (22.9%)
Women 432 (24.1%) 421 (23.5%) 514 (28.7%) 427 (23.8%)
No. of participants with SCC (%) 85 (24.9%) 90 (26.4%) 78 (22.9%) 88 (25.8%)
Men 53 (26.1%) 54 (26.6%) 40 (19.7%) 56 (27.6%)
Women 32 (23.2%) 36 (26.1%) 38 (27.5%) 32 (23.2%)
Mean age at entry (years±SD)
Men 55.9±4.3 56.1±4.4 56.1±4.4 56.2±4.4
Women 56.0±4.4 56.0±4.3 56.4±4.4 56.7±4.4
Mean BMI (kg/m2±SD)
Men 22.4±1.3 25.0±0.6 27.0±0.6 30.9±2.8
Women 20.5±1.2 23.0±0.6 25.4±0.9 30.8±3.6
Mean waist circumference (cm±SD)
Men 85.9±5.6 92.2±4.9 96.9±5.0 106.4±8.4
Women 71±5.2 76.1±5.3 81.7±6.0 93.8±9.9
Mean hip circumference (cm±SD)
Men 94.3±4.4 98.3±4.0 101±4.1 106.5±6.3
Women 93±4.6 97.6±4.3 102±4.7 110.5±8.3
Mean waist:hip ratio (ratio±SD)
Men 0.9±0.1 0.9±0.1 1.0±0.1 1.0±0.1
Women 0.8±0.1 0.8±0.1 0.8±0.1 0.9±0.1
Abbreviations: BCC, basal cell carcinoma; BMI, body mass index; MM, malignant melanoma; No., number; SCC, squamous cell carcinoma; SD, standard
deviation.
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study was that we were unable to adjust
for the direct UVR exposure acquired by
each individual as we had no
information of sun seeking behavior or
use of tanning beds. As it has been
suggested that obese people have a
different UVR seeking behavior com-
pared with lean people (e.g., spend
less time outdoors and avoid sunbathing)
(Gerstenblith et al., 2012), the inverse
associations observed between obesity
and risk for NMSC may therefore at least
partly be influenced by unmeasured
confounding by UVR exposure.
Several strengths of this study are note-
worthy. First, the vast majority of earlier
studies only included BMI, whereas we
also addressed the association between
other anthropometric measures and risk
for skin cancer. However, as we found
no conspicuous patterns of associations
between the different anthropometric
measures and risk for skin cancer, we
were unable to draw firm conclusions
about whether general, abdominal, or
gluteofemoral obesity is the best mea-
sure for analyzing potential associations
with skin cancer. Another strength was
that the anthropometric measures were
obtained prospectively by healthcare
professionals using standardized methods,
thus minimizing the possibility of differ-
ential recall bias. The study population
Table 2. HRs for BCC among 26,685 men and 29,243 women according to anthropometric measures
Anthropometric measure
Men Women
Cases/male cohort Adjusted HR (95% CI)1 Cases/female cohort Adjusted HR (95% CI)1
1,671/26,685 1,794/29,243
BMI 2
1st quartile 429/5,775 1.00 432/5,326 1.00
2nd quartile 475/6,130 1.07 (0.93–1.23) 421/5,924 0.88 (0.76–1.01)
3rd quartile 384/5,609 1.00 (0.85–1.18) 514/7,717 0.83 (0.72–0.97)
4th quartile 383/7,500 0.85 (0.69–1.05) 427/8,482 0.67 (0.54–0.82)
Per 2 kg m2 0.96 (0.90–1.01) 0.90 (0.86–0.94)
Waist circumference3
1st quartile 465/6,348 1.00 497/6,234 1.00
2nd quartile 488/6,414 1.05 (0.92–1.21) 445/6,574 0.90 (0.79–1.03)
3rd quartile 382/5,722 0.97 (0.83–1.13) 397/6,377 0.86 (0.74–0.99)
4th quartile 336/6,530 0.83 (0.68–1.01) 455/8,264 0.85 (0.72–1.01)
Per 5 cm 0.94 (0.90–0.98) 0.96 (0.93–0.99)
Hip circumference4
1st quartile 496/6,843 1.00 487/6,370 1.00
2nd quartile 454/6,493 0.99 (0.87–1.14) 482/6,934 0.95 (0.83–1.08)
3rd quartile 401/5,688 1.08 (0.92–1.25) 402/6,270 0.92 (0.80–1.06)
4th quartile 320/5,990 0.94 (0.77–1.14) 423/7,875 0.86 (0.72–1.02)
Per 5 cm 0.98 (0.92–1.04) 0.96 (0.92–1.00)
Waist:hip ratio5
1st quartile 468/6,307 1.00 494/6,809 1.00
2nd quartile 467/6,595 0.96 (0.85–1.09) 476/6,341 1.04 (0.91–1.18)
3rd quartile 415/6,064 0.94 (0.82–1.07) 447/8,053 0.78 (0.69–0.89)
4th quartile 321/6,048 0.78 (0.68–0.91) 377/6,246 0.88 (0.77–1.01)
Per 0.05 unit 0.93 (0.89–0.97) 0.94 (0.91–0.98)
Abbreviations: BCC, basal cell carcinoma; BMI, body mass index; CI, confidence interval; HR, hazard ratio.
1Adjusted for age, sun sensitivity (redness, pain, and blistering; redness, pain, and peeling; redness, then tan, or only tan), degree of freckling (none, few,
moderate, or many), and number of nevi (none, few, moderate, or many). Further, BMI is adjusted for waist circumference, and waist circumference and hip
circumference are mutually adjusted.
2BMI quartiles, men: 1:p24 kg m 2, 2:424–p 26 kg m2, 3:426–p 28 kg m2, 4:428 kg m2; women: 1:p22 kg m 2, 2:422–p 24 kg m2, 3:424–
p 27 kg m 2, 4:427 kg m2.
3Waist circumference quartiles, men: 1:p89 cm, 2:489–p95 cm, 3:495–p101 cm, 4:4101 cm; women: 1:p73 cm, 2:473–p 79 cm, 3:479–p 86 cm,
4:486 cm.
4Hip circumference quartiles, men: 1:p96 cm, 2:496–p 100 cm, 3:4100–p104 cm, 4104 cm; women: 1:p95 cm, 2:495–p100 cm, 3: 4100–p105 cm,
4: 4105 cm.
5Waist:hip ratio quartiles, men: 1:p0.91, 2:40.91–p 0.95, 3:40.95–p 0.99, 4:40.99; women: 1:p0.75, 2:40.75–p 0.79, 3:40.79–p0.85, 4:40.85.
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was randomly selected from the back-
ground population, and there was virtually
no loss to follow-up because of the precise
linkage between the study cohort and
various Danish health registries.
In conclusion, the results of this large
population-based cohort study showed
no convincing association between obe-
sity and risk for MM, whereas inverse
associations were found between var-
ious anthropometric measures and risk
for BCC in both genders and for SCC
among women only. Additional studies
with more accurate data on exposure to
UVR are needed to investigate the role
of obesity in skin cancer pathogenesis.
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TO THE EDITOR
We report a total population study on
the incidence and mortality of neurofi-
bromatosis 1 (NF1) and 2 (NF2). The
results show that the birth incidence
of NF1 is higher than that generally
reported. These results also show that
this life-threatening disease is more
deleterious to women than to men.
NF1 is an autosomal dominant
neurocutaneous disease caused by
mutations in the NF1 gene on chromo-
some 17 (for review see Jouhilahti et al.,
2011). NF2 is also a dominantly
inherited disease, but caused by
mutations in the NF2 gene on chromo-
some 22 (Rouleau et al., 1993). An
important milestone for NF studies was
the consensus conference of National
Institutes of Health (NIH) in 1987,
which outlined the clinical diagnostic
criteria for NF1 and NF2 (Stumpf et al.,
1988). Four main diagnostic signs of
NF1 are visible in skin: cafe´-au-lait
spots, dermal neurofibromas, axillary
freckles, and some plexiform neuro-
fibromas. The hallmarks of NF2 include
bilateral vestibular schwannomas, other
schwannomas, and intracranial menin-
geomas (Evans et al., 1992).
Most of the NF1 epidemiological
studies report prevalences between
1/3,000 and 1/6,000 and birth incidence
with estimates varying between 1/2,558Accepted article preview online 29 October 2014; published online 4 December 2014
Abbreviations: ICD, International Classification of Diseases; NF, neurofibromatosis; SMR, standardized
mortality ratio
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